🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Not all #prostatecancer BCRs are created equally!!🚨 👉Many interesting takeaways in this Swedish population-based study after prostatectomy JNCI 1⃣Half of pts w/ high-risk PCa recur within 10 years 2⃣Death from PCa at 10yr was 9% for high-risk European Association of Urology (EAU) BCR & 2.2% for

Would renaming Gleason Score 6 prostate cancer as non-cancer lead to better outcomes? Listen to our latest podcast with Prof. Scott Eggener Scott Eggener as we explore this important and timely debate.European Association of Urology (EAU) Society of Urologic Oncology European Society of Residents in Urology EAU Young Academics

📹 In this expert video discussion, UROONCO PCa Assoc. Prof. Pawel Rajwa is joined by Prof. Gert De Meerleer & Dr. Roderick van den Bergh to talk about the management of biochemical recurrence in #prostatecancer. Watch here 👇 prostate.uroonco.uroweb.org/video/treatmen…

What is the role of #PSA response in androgen receptor pathway inhibitors (#ARPI)? eu-focus.europeanurology.com/article/S2405-… Shahrokh F. Shariat Axel S. Merseburger Alberto Briganti Pawel Rajwa silke gillessen

PSA decline = survival signal in advanced #ProstateCancer In a meta-analysis of 14 studies (n=8883), PSA response to ADT+ARPI was consistently associated with better OS across mHSPC, nmCRPC & mCRPC. A potential early (surrogate?) marker of efficacy. pubmed.ncbi.nlm.nih.gov/40379533/

I feel truly honoured to lead this important first-in-human trial using the Virtuoso Robotic System for something that is very close to my heart - En bloc resection of bladder tumour. #UroSoMe (1/n) youtu.be/gTUv-cq-ICI?si…

A new systematic review & meta-analysis explores the role of androgen receptor pathway inhibitor (ARPI) monotherapy across prostate cancer stages. •⚖️ Similar overall safety to ADT or ARPI+ADT combo •❤️‍🔥 Fewer hot flushes •⚠️ More breast-related side effects (pain &

A key study from our team explores the role of ARPI monotherapy in prostate cancer. Findings suggest: Toxicity is comparable to ARPI+ADT combination and ADT Each regimen shows distinct AE & QoL profiles ARPI may offer greater oncologic activity than ADT

The positive CREST study (BCG + Sasanlimab) in NMIBC was published today (Neal Shore et al). #ASCO25

#ASCO25 #ProstateCancer AMPLITUDE Trial 👉 PARPi in HRR+ mHSPC ▶️NIRA+AAP vs AAP ▶️ Better rPFS (HR 0.63; p=0.0001), particularly in those with BRCA1/2 alterations (HR 0.52; p<0.0001) Neeraj Agarwal, MD, FASCO 👏

Have presented “Replace Gleason score with quantification of pattern 4 (after suitable research)” to > 30 different prostate cancer groups. Despite radical premise – change fundamental basis of treatment – remarkably little push back: it just seems kind of obvious to most folks.

🎧 In today's episode of #EAUPodcasts, Assoc. Prof. Pawel Rajwa (PL) speaks with Prof. Peter Carroll (US) about the shifting landscape of active surveillance for intermediate-risk #PCa. Listen to the podcast here to learn more 👇 uroweb.org/education-even…

So proud of my team !!! 😎European Urology Oncology we have a rise of one point of our impact factor over the last year. Congrats for the great achievement Renu Eapen Riccardo Campi Alicia Morgans, MD, MPH Elena Castro Ashish M. Kamat, MD, MBBS Jeremy Teoh Laura Marandino Ploussard Guillaume we deliver for European Association of Urology (EAU)

In this week's 🎧 episode of #EAUPodcasts, Dr. Marcin Miszczyk and Prof. Wolfgang Fendler discussed the role of PSMA-PET imaging in modern #ProstateCancer management. Learn more 👇 uroweb.org/education-even…

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 David Olmos Elena Castro Daniel Castellano Annals of Oncology Tom Powles Advanced Prostate Cancer Consensus Conference OncoAlert

PEACE-3: Enzalutamide + Radium-223 improved rPFS (19.4 vs 16.4 mo) and OS (42.3 vs 35.0 mo) in mCRPC with bone mets. ⚠️Fracture risk ⬆️ BUT mandatory bone-targeting agents ⬇️ it. tombal silke gillessen Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology Annals of Oncology OncoAlert

Thank you for the honourable mention Declan Murphy, Nikita Bhatt & Mr Eoin Dinneen in the latest European Urology podcast! 👉 Read our #PARADIGM editorial here: doi.org/10.1016/j.euru… Watch this space... 👀

Early salvage RT matches adjuvant RT outcomes while reducing overtreatment in prostate cancer recurrence. Add PSMA-PET + short-term ADT or ARPI for better risk-adapted control, especially in high-risk BCR. Shahrokh F. Shariat Marcin Miszczyk Pawel Rajwa journals.lww.com/co-urology/ful…

Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer jnj.com/media-center/p…